Generate the anatomy and physiology of the 11 human body system l
| System | Key Organs | Primary Functions |
|---|---|---|
| Integumentary | Skin, hair, nails, glands | Protection, thermoregulation, sensation, Vitamin D |
| Skeletal | 206 bones, cartilage, joints | Support, protection, movement, hematopoiesis, mineral storage |
| Muscular | Skeletal, cardiac, smooth muscle | Locomotion, posture, heat production, visceral movement |
| Nervous | Brain, spinal cord, nerves | Communication, integration, control, sensation |
| Endocrine | Pituitary, thyroid, adrenals, pancreas, gonads | Hormone-based regulation, metabolism, reproduction, growth |
| Cardiovascular | Heart, arteries, veins, capillaries | Pumps blood, distributes O₂/nutrients, removes CO₂/waste |
| Respiratory | Lungs, airways, respiratory muscles | Gas exchange (O₂ in, CO₂ out), acid-base balance |
| Digestive | Mouth → anus, liver, pancreas | Ingestion, digestion, absorption, elimination |
| Urinary | Kidneys, ureters, bladder, urethra | Filtration, excretion, fluid/electrolyte/acid-base balance |
| Reproductive | Gonads, ducts, accessory organs | Gamete production, fertilization, development |
| Lymphatic/Immune | Thymus, lymph nodes, spleen, lymphatics | Fluid return, immune surveillance, pathogen defense |
And its disease example
| Disease | Type | Key Features |
|---|---|---|
| Melanoma | Malignant | Uncontrolled growth of melanocytes; ABCDE criteria (Asymmetry, Border, Color, Diameter, Evolving); linked to UV exposure; can metastasize widely |
| Psoriasis | Autoimmune | T-cell mediated hyperproliferation of keratinocytes; thick, silvery plaques on extensor surfaces; Koebner phenomenon |
| Atopic Dermatitis (Eczema) | Inflammatory/Allergic | Defective filaggrin in stratum corneum → impaired barrier; intense pruritus, erythema, lichenification; strongly associated with asthma and allergic rhinitis |
| Basal Cell Carcinoma | Malignant | Most common skin cancer; arises from basal layer of epidermis; pearly, rolled edges with central ulceration; rarely metastasizes |
| Burns | Traumatic | Loss of barrier, fluid/electrolyte shifts (Parkland formula for resuscitation), infection risk; classified by depth (superficial, partial thickness, full thickness) |
| Cellulitis | Infectious | Bacterial (Staph/Strep) infection of dermis and subcutaneous tissue; erythema, warmth, swelling, pain; risk of sepsis if untreated |
| Disease | Type | Key Features |
|---|---|---|
| Osteoporosis | Metabolic | Decreased bone mineral density (BMD); imbalance between osteoclast resorption and osteoblast formation; T-score ≤ -2.5 on DEXA; risk of fragility fractures (hip, vertebral, wrist) - Goldman-Cecil Medicine |
| Osteoarthritis | Degenerative | Breakdown of articular cartilage (loss of proteoglycans, chondrocyte death); subchondral bone sclerosis, osteophytes, joint space narrowing; affects weight-bearing joints (knees, hips) |
| Rheumatoid Arthritis | Autoimmune | Synovitis driven by anti-CCP and RF antibodies; pannus formation erodes cartilage and bone; symmetric small joint involvement; systemic inflammation |
| Osteosarcoma | Malignant | Most common primary bone malignancy in adolescents; arises in metaphysis of long bones; "sunburst" pattern on X-ray; associated with Rb gene mutations |
| Paget's Disease of Bone | Metabolic | Excessive and disorganized bone remodeling; elevated ALP; can cause deafness, skull enlargement, pathological fractures; treated with bisphosphonates |
| Rickets/Osteomalacia | Nutritional | Vitamin D deficiency → impaired calcium/phosphate deposition in osteoid; soft bones; bowing of legs in children; Looser zones on X-ray in adults |
| Disease | Type | Key Features |
|---|---|---|
| Duchenne Muscular Dystrophy (DMD) | Genetic | X-linked recessive; dystrophin gene mutation → absent dystrophin protein → sarcolemmal fragility → progressive muscle necrosis; Gowers' sign; CK markedly elevated; cardiomyopathy |
| Myasthenia Gravis | Autoimmune | Antibodies against nicotinic ACh receptors at NMJ → impaired neuromuscular transmission; fatigable weakness (ptosis, diplopia, bulbar weakness); Tensilon (edrophonium) test positive |
| Rhabdomyolysis | Traumatic/Metabolic | Massive skeletal muscle breakdown → myoglobin release → acute kidney injury; elevated CK >10,000 U/L; dark (tea-colored) urine |
| Polymyositis/Dermatomyositis | Autoimmune/Inflammatory | CD8⁺ T-cell attack on muscle fibers (polymyositis); Gottron's papules, heliotrope rash (dermatomyositis); proximal muscle weakness; elevated CK and aldolase |
| Compartment Syndrome | Traumatic | Increased pressure within a fascial compartment → ischemia; 5 P's: Pain (with passive stretch), Pallor, Paresthesia, Paralysis, Pulselessness; surgical emergency |
| Disease | Type | Key Features |
|---|---|---|
| Ischemic Stroke | Vascular | Thromboembolic or lacunar occlusion of cerebral arteries → neuronal death within minutes (ischemic penumbra); FAST acronym; tPA within 4.5 hours; thrombectomy up to 24 hours |
| Alzheimer's Disease | Neurodegenerative | Amyloid-beta plaques and neurofibrillary tangles (tau protein); progressive episodic memory loss, aphasia, apraxia; medial temporal lobe (hippocampus) affected first |
| Multiple Sclerosis (MS) | Autoimmune | Demyelination of CNS white matter by autoreactive T-cells; relapsing-remitting most common; oligoclonal bands in CSF; MRI - periventricular plaques |
| Parkinson's Disease | Neurodegenerative | Loss of dopaminergic neurons in substantia nigra → dopamine depletion in striatum; TRAP: Tremor (resting, pill-rolling), Rigidity (cogwheel), Akinesia, Postural instability; Lewy bodies |
| Epilepsy | Neurological | Recurrent seizures from abnormal synchronized neuronal discharge; focal or generalized; EEG abnormalities; treated with antiepileptics targeting Na⁺/Ca²⁺ channels or GABA |
| Meningitis | Infectious | Bacterial (N. meningitidis, S. pneumoniae) or viral (enteroviruses) inflammation of meninges; classic triad: fever, neck stiffness, photophobia; CSF analysis is diagnostic |
| Guillain-Barré Syndrome | Autoimmune | Post-infectious ascending demyelinating polyneuropathy; areflexia, ascending weakness; cytoalbuminous dissociation in CSF (high protein, normal cells); IVIG or plasmapheresis |
| Disease | Type | Key Features |
|---|---|---|
| Type 1 Diabetes Mellitus | Autoimmune | Autoimmune destruction of beta cells (HLA-DR3/DR4 linked) → absolute insulin deficiency → hyperglycemia, DKA risk; requires lifelong insulin; onset typically in childhood/young adults - Guyton & Hall |
| Type 2 Diabetes Mellitus | Metabolic | Peripheral insulin resistance + progressive beta-cell failure; hyperglycemia, dyslipidemia, hypertension (metabolic syndrome); HbA1c used for monitoring; can lead to nephropathy, retinopathy, neuropathy, vasculopathy - Guyton & Hall |
| Hypothyroidism | Deficiency | Low T3/T4 → decreased BMR; weight gain, cold intolerance, bradycardia, constipation, myxedema; most common cause: Hashimoto's thyroiditis (autoimmune); treated with levothyroxine |
| Hyperthyroidism (Graves' Disease) | Autoimmune | TSH-receptor stimulating antibodies → excess T3/T4; weight loss, heat intolerance, tachycardia, exophthalmos, pretibial myxedema; treated with antithyroids, radioiodine, or thyroidectomy |
| Cushing's Syndrome | Hormonal excess | Excess glucocorticoids (most common cause: exogenous steroids; endogenous: ACTH-secreting pituitary adenoma = Cushing's disease); central obesity, moon face, buffalo hump, striae, hypertension, diabetes, osteoporosis |
| Addison's Disease | Deficiency | Primary adrenal insufficiency; cortisol and aldosterone deficiency; hypotension, hyponatremia, hyperkalemia, hyperpigmentation (elevated ACTH); can precipitate life-threatening adrenal crisis |
| Acromegaly | Hormonal excess | Excess GH in adults (usually pituitary adenoma) → excess IGF-1; coarsening of facial features, enlarged hands/feet, macroglossia, sleep apnea, diabetes, cardiomegaly |
| Disease | Type | Key Features |
|---|---|---|
| Acute Myocardial Infarction (MI) | Ischemic | Rupture of atherosclerotic plaque → coronary thrombosis → myocardial necrosis; STEMI vs NSTEMI (based on ECG and troponin); "time is muscle" - reperfusion via PCI or thrombolysis - Braunwald's Heart Disease |
| Heart Failure | Functional | Reduced cardiac output to meet metabolic demands; systolic (reduced EF) or diastolic (preserved EF) dysfunction; Framingham criteria; Starling law derangement; RAAS activation perpetuates fluid retention - Brenner and Rector's Kidney |
| Hypertension | Vascular | Sustained BP >130/80 mmHg; silent killer; damages target organs (heart, kidney, brain, eyes, vessels); essential (95%) vs secondary; treated with lifestyle + antihypertensives (ACEi, ARBs, CCBs, thiazides) |
| Atrial Fibrillation | Arrhythmia | Chaotic atrial electrical activity; irregularly irregular pulse; stroke risk (Virchow's triad in left atrial appendage); CHA₂DS₂-VASc score for anticoagulation; rate vs rhythm control |
| Infective Endocarditis | Infectious | Bacterial (Streptococcus, Staphylococcus) infection of cardiac valves; vegetation formation → valve destruction, emboli; Osler's nodes, Janeway lesions, Roth spots; Duke criteria for diagnosis |
| Deep Vein Thrombosis / PE | Thromboembolic | Virchow's triad (stasis, hypercoagulability, endothelial damage); DVT → pulmonary embolism; Wells score, D-dimer, CT pulmonary angiography; anticoagulation treatment |
| Disease | Type | Key Features |
|---|---|---|
| Asthma | Obstructive/Inflammatory | Reversible airway bronchoconstriction, inflammation, hyperresponsiveness; triggered by allergens, exercise, cold, infections; eosinophilic inflammation; β₂-agonists (acute relief), inhaled corticosteroids (maintenance) |
| COPD | Obstructive (irreversible) | Emphysema (alveolar wall destruction, loss of elastic recoil) + chronic bronchitis ("blue bloater" - excess mucus, cough ≥3 months/2 years); FEV₁/FVC <0.70; caused by smoking; managed with bronchodilators, pulmonary rehab |
| Pneumonia | Infectious | Alveolar consolidation by bacteria (S. pneumoniae most common), viruses, or fungi; lobar, broncho-, or interstitial patterns; productive cough, fever, crackles; CXR consolidation |
| Pulmonary Embolism (PE) | Vascular | DVT fragment lodges in pulmonary vasculature → V/Q mismatch, right heart strain; sudden dyspnea, pleuritic chest pain, hemoptysis; Wells score + CTPA for diagnosis |
| Idiopathic Pulmonary Fibrosis (IPF) | Restrictive/Fibrotic | Progressive fibrosis of alveolar walls → reduced compliance, reduced DLCO; "honeycomb" pattern on HRCT; UIP pattern on biopsy; no cure, nintedanib/pirfenidone slow progression |
| Lung Cancer | Malignant | Non-small cell (adenocarcinoma, squamous cell) vs small-cell (SCLC); strongly linked to smoking; para-neoplastic syndromes; EGFR/ALK mutations guide targeted therapy |
| Tuberculosis (TB) | Infectious | Mycobacterium tuberculosis; latent vs active; Ghon complex (primary); cavitary lesions (secondary reactivation); acid-fast bacilli on smear; RIPE therapy |
| Disease | Type | Key Features |
|---|---|---|
| Inflammatory Bowel Disease (IBD) | Autoimmune/Inflammatory | Two major forms: Crohn's disease (transmural inflammation, any GI segment, skip lesions, granulomas, cobblestoning) and Ulcerative colitis (mucosal inflammation, rectum to colon, continuous, pseudopolyps); complex polygenic disorders with peak incidence in 2nd-4th decade - Goldman-Cecil Medicine |
| Peptic Ulcer Disease (PUD) | Inflammatory | Mucosal erosion into submucosa/muscularis; H. pylori infection (70% of duodenal, 90% of gastric) + NSAIDs disrupt mucosal defense; epigastric pain, GI bleeding (hematemesis, melena) |
| Cirrhosis | Fibrotic/End-stage | Hepatocyte death → fibrosis → nodular regeneration; causes: alcohol, NAFLD, viral hepatitis (B, C); portal hypertension (varices, splenomegaly, ascites), hepatic encephalopathy, coagulopathy, jaundice |
| Colorectal Cancer | Malignant | Adenoma → carcinoma sequence (APC gene mutation); FAP (familial polyposis); Lynch syndrome (MSI); screening by colonoscopy; change in bowel habits, rectal bleeding |
| Acute Pancreatitis | Inflammatory | Premature activation of pancreatic enzymes → auto-digestion; causes: gallstones (most common), alcohol; epigastric pain radiating to back, elevated lipase/amylase; Ranson criteria for severity |
| Gastroesophageal Reflux Disease (GERD) | Functional/Inflammatory | Lower esophageal sphincter dysfunction → acid reflux; heartburn, regurgitation; Barrett's esophagus (columnar metaplasia) → adenocarcinoma risk; treated with PPIs |
| Disease | Type | Key Features |
|---|---|---|
| Chronic Kidney Disease (CKD) | Degenerative | Progressive irreversible loss of renal function; causes: hypertension, diabetes (nephrosclerosis), chronic glomerulonephritis, polycystic kidney disease; GFR <60 mL/min for >3 months = CKD; stages 1-5 (ESRD at stage 5) - Henry's Clinical Diagnosis |
| Acute Kidney Injury (AKI) | Functional | Sudden decline in GFR; prerenal (hypovolemia, shock), intrinsic (ATN, glomerulonephritis), postrenal (obstruction); KDIGO criteria; oliguria, rising creatinine, electrolyte disturbances |
| Nephrotic Syndrome | Glomerular | Massive proteinuria (>3.5 g/day) → hypoalbuminemia → edema, hyperlipidemia, lipiduria; causes: minimal change disease (children), focal segmental glomerulosclerosis, membranous nephropathy |
| Nephritic Syndrome | Glomerular | Hematuria (RBC casts), hypertension, oliguria, mild proteinuria; causes: post-streptococcal GN, IgA nephropathy (most common worldwide), lupus nephritis, Goodpasture's |
| Urinary Tract Infection (UTI) | Infectious | E. coli most common; cystitis (lower): dysuria, frequency, urgency; pyelonephritis (upper): flank pain, fever, costovertebral tenderness; urine culture guides antibiotic therapy |
| Renal Cell Carcinoma (RCC) | Malignant | Clear cell (most common, VHL gene); classic triad: hematuria, flank pain, palpable mass; paraneoplastic syndromes (erythrocytosis, hypercalcemia); treated with nephrectomy + targeted therapy (sunitinib) |
| Polycystic Kidney Disease (PKD) | Genetic | Autosomal dominant (PKD1/PKD2 mutations); progressive cyst enlargement → CKD; hypertension, hematuria; associated with berry aneurysms, mitral valve prolapse, liver cysts |
| Disease | Type | Key Features |
|---|---|---|
| Polycystic Ovary Syndrome (PCOS) | Endocrine/Reproductive | Androgen excess, oligoanovulation, polycystic ovaries; insulin resistance; irregular periods, hirsutism, acne, infertility; Rotterdam criteria (2 of 3 features); managed with OCPs, metformin, clomiphene |
| Endometriosis | Inflammatory | Ectopic endometrial tissue outside uterus (ovaries, pelvic peritoneum); cyclical pain, dysmenorrhea, dyspareunia, infertility; chocolate cysts (endometriomas); laparoscopy is gold standard for diagnosis |
| Benign Prostatic Hyperplasia (BPH) | Hyperplastic | DHT-driven stromal and glandular hyperplasia of transitional zone; lower urinary tract symptoms (LUTS): hesitancy, weak stream, nocturia; PSA may be elevated; α-blockers and 5α-reductase inhibitors |
| Prostate Cancer | Malignant | Most common male cancer (after skin); adenocarcinoma of peripheral zone; PSA screening; Gleason score; BRCA2 mutations increase risk; androgen deprivation therapy for advanced disease |
| Cervical Cancer | Malignant | HPV 16/18 infection → squamous cell carcinoma or adenocarcinoma; preventable with HPV vaccine; screened with Pap smear + HPV co-testing; radical hysterectomy or radiation/chemotherapy |
| Ectopic Pregnancy | Obstetric | Implantation outside uterus (usually fallopian tube ampulla); rupture → hemorrhage, shock; hCG rises abnormally slowly; transvaginal ultrasound diagnostic; methotrexate (early) or surgery |
| Testicular Cancer | Malignant | Most common solid cancer in young men (15-35 yrs); germ cell tumors (seminoma, non-seminoma); painless testicular mass; elevated AFP, β-hCG, LDH; highly curable with chemotherapy (BEP regimen) |
| Disease | Type | Key Features |
|---|---|---|
| Hodgkin Lymphoma | Malignant | Reed-Sternberg cells (B-cell origin, CD15⁺/CD30⁺); bimodal age distribution; painless lymphadenopathy, B symptoms (fever, night sweats, weight loss); highly curable with ABVD chemotherapy |
| Non-Hodgkin Lymphoma (NHL) | Malignant | Heterogeneous group; B-cell (diffuse large B-cell, follicular, Burkitt's) or T-cell; Burkitt's - c-Myc translocation t(8;14); associated with HIV, EBV, immunosuppression - Harrison's Principles |
| Leukemia | Malignant | Malignant proliferation of hematopoietic cells; ALL (childhood, B or T-cell), AML (adults), CLL (B-cell, elderly - most common adult leukemia), CML (BCR-ABL t(9;22) Philadelphia chromosome → imatinib) - Harrison's Principles |
| HIV/AIDS | Infectious/Immune | HIV destroys CD4⁺ T-helper cells → progressive immunodeficiency; AIDS: CD4 <200/µL or AIDS-defining illness; opportunistic infections (PCP, CMV, toxoplasmosis, Cryptococcus); ART (antiretroviral therapy) |
| Systemic Lupus Erythematosus (SLE) | Autoimmune | Multi-system autoimmune disease; anti-dsDNA and anti-Smith antibodies; malar rash, photosensitivity, oral ulcers, serositis, glomerulonephritis, cytopenias; SLICC criteria |
| Lymphedema | Lymphatic obstruction | Impaired lymph drainage → protein-rich interstitial fluid accumulation; primary (Milroy's disease) or secondary (post-mastectomy, filariasis); non-pitting edema; irreversible fibrosis if untreated |
| Anaphylaxis | Immune/Allergic | IgE-mediated mast cell and basophil degranulation → massive histamine, leukotrienes, prostaglandins release; urticaria, angioedema, bronchospasm, hypotension; epinephrine IM is first-line treatment |
| Common Variable Immunodeficiency (CVID) | Primary Immunodeficiency | Low immunoglobulins, poor vaccine responses; recurrent sinopulmonary infections; increased risk of autoimmunity and lymphoma; treated with IVIG replacement |
| Body System | Key Diseases (Examples) | Core Mechanism |
|---|---|---|
| Integumentary | Melanoma, Psoriasis, Eczema, Cellulitis | Barrier disruption, aberrant inflammation, malignant transformation |
| Skeletal | Osteoporosis, Osteoarthritis, RA, Osteosarcoma | Remodeling imbalance, cartilage degeneration, autoimmunity, malignancy |
| Muscular | DMD, Myasthenia Gravis, Rhabdomyolysis | Structural protein defect, NMJ dysfunction, muscle breakdown |
| Nervous | Stroke, Alzheimer's, MS, Parkinson's, Epilepsy | Ischemia, neurodegeneration, demyelination, dopamine loss, dysrhythmia |
| Endocrine | DM Type 1 & 2, Hypothyroidism, Cushing's, Addison's | Hormone deficiency or excess, receptor resistance, gland destruction |
| Cardiovascular | MI, Heart Failure, Hypertension, AF | Atherosclerosis, pump failure, increased vascular resistance, arrhythmia |
| Respiratory | Asthma, COPD, Pneumonia, IPF, Lung Cancer | Airway obstruction, inflammation, fibrosis, infection, malignancy |
| Digestive | IBD, PUD, Cirrhosis, Colorectal Cancer, Pancreatitis | Mucosal damage, autoimmunity, fibrosis, malignant transformation |
| Urinary | CKD, AKI, Nephrotic Syndrome, UTI, PKD | Nephron loss, filtration failure, glomerular damage, obstruction, infection |
| Reproductive | PCOS, Endometriosis, Prostate/Cervical Cancer, Ectopic | Hormonal imbalance, ectopic tissue, HPV/oncogene-driven malignancy |
| Lymphatic/Immune | HIV/AIDS, SLE, Leukemia, Lymphoma, Anaphylaxis | Immunodeficiency, autoimmunity, malignant lymphoproliferation, dysregulated IgE |
Difference between in dm 1 and dm 2 with explanation lije a story And body blood flow of oxygenated blood and deoxygenated blood exchange explain
"In type 1 diabetes, a complex interplay of genetic, environmental, and autoimmune factors selectively targets insulin-producing pancreatic islet β cells and ultimately destroys them... β-cell destruction is largely mediated by CD8+ and CD4+ T cells, macrophages - causing apoptosis or cellular destruction." - Goldman-Cecil Medicine
| DM Type 1 Quick Facts | |
|---|---|
| Who | Children, teenagers, young adults (but can occur at any age) |
| What happened | Beta cells completely destroyed by autoimmunity |
| Insulin level | Zero (absolute deficiency) |
| Antibodies | Anti-GAD65, anti-IA-2, anti-ZnT8, anti-insulin |
| Genes | HLA DR3-DQ2 / DR4-DQ8 on chromosome 6 (~50% of risk) |
| Onset | Sudden, dramatic - often presents in DKA |
| Body type | Usually thin/normal weight |
| Treatment | Insulin - always, no exceptions |
"Type 2 diabetes: a combination of insulin resistance and defective insulin secretion." - Henry's Clinical Diagnosis
| DM Type 2 Quick Facts | |
|---|---|
| Who | Middle-aged and older adults; increasingly younger due to obesity |
| What happened | Insulin resistance + gradual beta-cell exhaustion |
| Insulin level | Normal or HIGH early on; low later as beta cells fail |
| Antibodies | Usually none |
| Risk factors | Obesity (especially visceral), inactivity, family history, ethnicity |
| Onset | Slow, silent - often found incidentally on routine testing |
| Body type | Usually overweight/obese |
| Treatment | Lifestyle, metformin, GLP-1 agonists, SGLT2 inhibitors, eventually insulin |
| Feature | Type 1 DM | Type 2 DM |
|---|---|---|
| The story | Key factory destroyed | Locks became rusty |
| Core defect | Absolute insulin deficiency | Insulin resistance + relative insulin deficiency |
| Cause | Autoimmune (T-cell mediated) | Metabolic/lifestyle + genetic |
| Age of onset | Usually <30 years | Usually >40 years (but rising in younger people) |
| Body weight | Usually normal/thin | Usually overweight/obese |
| Speed of onset | Rapid (days to weeks) | Slow (years to decades) |
| DKA | Common, can be first presentation | Rare (possible in severe illness - "ketosis-prone T2D") |
| C-peptide | Very low/undetectable | Normal or elevated early; reduced later |
| Autoantibodies | Positive (GAD65, IA-2, ZnT8) | Negative |
| HLA association | DR3-DQ2, DR4-DQ8 | Not HLA-linked; TCF7L2, KCNJ11, PPARG genes |
| Twin concordance | 30-40% (identical twins) | ~70-90% (identical twins) |
| Insulin needed? | Always, from diagnosis | Only after beta-cell failure; many manage without |
| Reversible? | No - beta cells permanently gone | Partially - early T2D can remit with weight loss |
| Complications | Both share: retinopathy, nephropathy, neuropathy, cardiovascular disease |

Body tissues
↓ (used up O₂, full of CO₂)
Superior Vena Cava + Inferior Vena Cava
↓
Right Atrium → [Tricuspid Valve] → Right Ventricle
↓ [Pulmonic Valve]
Pulmonary Trunk → Right + Left Pulmonary ARTERIES
↓ (the ONLY arteries carrying deoxygenated blood!)
Pulmonary Capillaries surrounding Alveoli
↓ GAS EXCHANGE HAPPENS HERE:
O₂ diffuses IN (alveolar PO₂ ~100 mmHg → blood ~40 mmHg)
CO₂ diffuses OUT (blood PCO₂ ~45 mmHg → alveoli ~40 mmHg)
↓ (now fresh, oxygenated, bright red blood)
Pulmonary VEINS (the ONLY veins carrying oxygenated blood!)
↓
Left Atrium
"Deoxygenated blood from the systemic circulation flows from the right atrium into the right ventricle and from there into the pulmonary circulation... the blood is enriched with oxygen and carbon dioxide is released into the airways. The oxygenated blood leaves the lungs by the pulmonary veins and flows to the left atrium." - Color Atlas of Human Anatomy Vol. 2
Left Atrium → [Mitral Valve] → Left Ventricle
↓ [Aortic Valve]
AORTA (pumped at 120 mmHg systolic - high pressure)
↓ branches into organ-specific arteries
├── Cerebral arteries → Brain (15% of cardiac output)
├── Coronary arteries → Heart muscle (5%)
├── Renal arteries → Kidneys (25%)
├── Mesenteric/celiac arteries → GI tract (25%)
├── Skeletal muscle arteries → Muscles (25% at rest, up to 80% during exercise)
└── Cutaneous arteries → Skin (5%)
↓ (at each organ: capillaries)
GAS EXCHANGE:
O₂ leaves blood → enters cells
CO₂ leaves cells → enters blood
Nutrients (glucose, amino acids) delivered
Waste products (CO₂, urea, lactic acid) collected
↓ (now deoxygenated, dark red blood)
├── Veins from legs/abdomen → Inferior Vena Cava
└── Veins from head/arms → Superior Vena Cava
↓
Right Atrium (cycle restarts)
"Oxygenated blood from the lung flows from the left atrium of the heart into the left ventricle. From there it is pumped through the aorta into the systemic circulation, which consists of numerous separate circuits supplying individual organs... At the capillary plexus, exchange of gases and metabolic products occurs." - Color Atlas of Human Anatomy Vol. 2
GI capillaries (nutrient-rich after eating)
↓
Portal Vein
↓
Liver sinusoids (hepatocytes process glucose, amino acids, toxins)
↓
Hepatic Veins
↓
Inferior Vena Cava → Right Atrium
| Gas | Direction | Driving Force |
|---|---|---|
| O₂ | Alveolus → Blood | PO₂ alveolus ~100 mmHg vs. blood ~40 mmHg |
| CO₂ | Blood → Alveolus | PCO₂ blood ~45 mmHg vs. alveolus ~40 mmHg |
| Gas | Direction | Driving Force |
|---|---|---|
| O₂ | Blood → Cell | PO₂ arterial blood ~95 mmHg vs. tissue ~40 mmHg |
| CO₂ | Cell → Blood | PCO₂ tissue ~46 mmHg vs. arterial blood ~40 mmHg |
breathing and exchange of gases explain in medical Coding Interview
gas exchange alveoli oxygen carbon dioxide diffusion diagram

This pathophysiology diagram illustrates the principles of gas exchange in an Extracorporeal Membrane Oxygenation (ECMO) circuit. The schematic depicts a closed-loop system where blood is diverted from the cardiopulmonary system (represented by lung and heart icons) to an extracorporeal membrane lung (ML), shown as a diamond-shaped oxygenator. A color gradient transitions from blue (deoxygenated) to red (oxygenated) as blood passes through the ML. The diagram includes physiological formulas for oxygen consumption (VO2-ML) and carbon dioxide removal (VCO2-ML) by the membrane lung, emphasizing their dependence on the extracorporeal blood flow (ECBF) and the content differences pre- and post-membrane. Key quantitative data include an ECBF range of 3-6 L/min and a metabolic VO2-VCO2 rate of 3-5 mL/kg/min. An oxygen tank icon indicates the exogenous O2 source, while CO2 exit is shown via an arrow. This educational visual is designed for advanced medical learners to understand the mechanical substitution of pulmonary gas exchange and the clinical variables governing ECMO efficiency.

This physiological trace diagram displays multiple respiratory and gas exchange parameters recorded over approximately two minutes and forty seconds during an experimental study on inspiratory resistance. The figure is organized into six vertically stacked panels: inspiratory pressure (cmH2O), respiratory bellows (arbitrary units), carbon dioxide (%), oxygen (%), breathing rate (BPM), and breathing depth (au). Five vertical gray bars indicate periods where an external inspiratory resistance of 55 cmH2O was applied. During these resistance periods, the 'Inspiratory Pressure' trace shows significant negative deflections, reaching approximately -15 cmH2O, reflecting increased inspiratory effort. The 'Carbon Dioxide' trace reveals rhythmic oscillations corresponding to the respiratory cycle; asterisks (*) are placed above the peaks immediately following each gray period to highlight an increase in end-tidal carbon dioxide (PETCO2). The 'Oxygen' trace shows inverse oscillations to CO2. The bottom panels utilize step-graphs to track dynamic changes in breathing frequency and volume (depth). This visualization demonstrates the acute physiological and compensatory responses of the respiratory system to sudden, external mechanical loads.

Educational diagnostic image demonstrating group statistical parametric maps (n=20) from an fMRI study. The figure illustrates the regional association between Blood Oxygen Level Dependent (BOLD) signal changes (ΔBOLD) and respiratory gas exchange (RGE) metrics: breath exchange ratio (bER), change in partial pressure of oxygen (ΔPO2), and change in partial pressure of carbon dioxide (ΔPCO2). Panel (A) displays group maps of regional ΔBOLD per unit change of these metrics (β values), showing widespread positive associations for bER and ΔPO2, while ΔPCO2 shows minimal significant association. Panel (B) presents the percentage of voxels with significant ΔBOLD associations, highlighting a higher density (over 50%) in gray matter regions for bER and ΔPO2 compared to white matter and compared to ΔPCO2. Panel (C) provides paired comparisons, specifically showing significant differences between bER and ΔPCO2 across subcortical regions and the brainstem. Color scales represent magnitude and percentage, with statistical significance corrected at pfdr < 0.05. The maps include axial, sagittal, and coronal anatomical views to demonstrate spatial distribution across the brain.
ICD-10 CPT medical coding respiratory breathing gas exchange codes interview questions 2025
https://www.thoracic.org/professionals/clinical-resources/re…
Brain sends signal → Diaphragm contracts (flattens downward)
+ External intercostal muscles contract (ribs swing up and out)
↓
Thoracic volume INCREASES
↓
Intrapleural pressure drops (from -5 to -8 cmH₂O)
↓
Alveolar pressure falls BELOW atmospheric pressure (760 mmHg)
↓
Air rushes IN (nature hates a pressure difference)
Diaphragm RELAXES → elastic recoil of lungs
↓
Thoracic volume DECREASES
↓
Alveolar pressure RISES above atmospheric
↓
Air flows OUT
| Volume/Capacity | Normal Value | Clinical Relevance |
|---|---|---|
| Tidal Volume (TV) | 500 mL | Volume per normal breath |
| IRV (Inspiratory Reserve) | ~3,100 mL | Extra air you CAN inhale |
| ERV (Expiratory Reserve) | ~1,200 mL | Extra air you CAN exhale |
| Residual Volume (RV) | ~1,200 mL | Air that NEVER leaves the lung |
| Total Lung Capacity (TLC) | ~6,000 mL | TV + IRV + ERV + RV |
| FVC | ~4,800 mL | Forced total expiration |
| FEV₁ | ~3,200 mL | Forced air in 1 second |
| FEV₁/FVC ratio | >0.70 | <0.70 = OBSTRUCTIVE disease |
Coding note: Spirometry (PFT) results directly determine whether you code obstructive (COPD - J44.x) vs restrictive (pulmonary fibrosis - J84.x) disease. Never assume - the documentation must state the diagnosis.
| Location | PO₂ (O₂) | PCO₂ (CO₂) |
|---|---|---|
| Atmospheric air | 159 mmHg | 0.3 mmHg |
| Alveoli | 100 mmHg | 40 mmHg |
| Deoxygenated blood arriving | 40 mmHg | 45 mmHg |
| Oxygenated blood leaving | 95-100 mmHg | 40 mmHg |
| Tissue cells (working muscle) | 20-40 mmHg | 46+ mmHg |
"Oxygen uptake via the lungs is dependent on both the partial pressure of oxygen and ventilation-perfusion matching." - Current Surgical Therapy 14e
| Form | Amount | Detail |
|---|---|---|
| Bound to Hemoglobin | 98.5% | Each Hb molecule carries 4 O₂; forms oxyhemoglobin |
| Dissolved in plasma | 1.5% | Measured as PaO₂ on ABG |
| Parameter | Normal Value | Range |
|---|---|---|
| pH | 7.40 | 7.35 - 7.45 |
| PaCO₂ | 40 mmHg | 38 - 42 mmHg |
| PaO₂ | 100 mmHg | 75 - 100 mmHg |
| HCO₃⁻ | 24 mEq/L | 22 - 26 mEq/L |
| SpO₂ | 95 - 100% | <91% = hypoxemia |
| Step | What to Check | What It Means |
|---|---|---|
| 1 | pH | <7.35 = Acidemia; >7.45 = Alkalemia |
| 2 | PaCO₂ | ↑CO₂ + ↓pH = Respiratory Acidosis |
| 3 | HCO₃⁻ | ↓HCO₃ + ↓pH = Metabolic Acidosis |
| 4 | Base Excess | >+4 = Alkalosis; <-4 = Acidosis |
| 5 | PaO₂ | <75 = Hypoxemia; identify cause |
| Disorder | pH | PaCO₂ | HCO₃⁻ | Common Cause |
|---|---|---|---|---|
| Respiratory Acidosis | ↓ | ↑ | ↑(comp) | COPD, hypoventilation, opioids |
| Respiratory Alkalosis | ↑ | ↓ | ↓(comp) | Hyperventilation, anxiety, PE |
| Metabolic Acidosis | ↓ | ↓(comp) | ↓ | DKA, lactic acidosis, renal failure |
| Metabolic Alkalosis | ↑ | ↑(comp) | ↑ | Vomiting, diuretics, NG suction |
Coding note: The ABG result does NOT give you a code - only the physician's documented diagnosis does. The ABG supports medical necessity and determines severity (e.g., acute vs chronic respiratory failure).
J00-J06 Acute upper respiratory infections
J09-J18 Influenza and pneumonia
J20-J22 Other acute lower respiratory infections
J30-J39 Other diseases of upper respiratory tract
J40-J47 Chronic lower respiratory diseases (COPD, Asthma)
J60-J70 Lung diseases due to external agents
J80-J84 Other respiratory diseases (interstitial lung diseases)
J85-J86 Suppurative/necrotic conditions of lower tract
J90-J94 Other diseases of the pleura
J96-J99 Other diseases of the respiratory system
| ICD-10 Code | Description | Key Documentation Needed |
|---|---|---|
| J44.0 | COPD with acute lower respiratory infection | Organism if known |
| J44.1 | COPD with acute exacerbation | Must say "acute exacerbation" |
| J44.9 | COPD, unspecified | Default COPD code |
| J45.20 | Mild intermittent asthma, uncomplicated | Frequency, severity, spirometry |
| J45.30 | Mild persistent asthma, uncomplicated | Same |
| J45.40 | Moderate persistent asthma, uncomplicated | Same |
| J45.50 | Severe persistent asthma, uncomplicated | Same |
| J45.901 | Unspecified asthma with acute exacerbation | |
| J43.1 | Panlobular emphysema | |
| J43.2 | Centrilobular emphysema | Specific CT findings required |
Interview tip: If a patient has both asthma and COPD with documented overlap, you can code both J44.x AND J45.x together. - ATS ICD-10 Pulmonary Guide
| ICD-10 Code | Description | Interview Key Point |
|---|---|---|
| J96.00 | Acute respiratory failure, unspecified | Use when hypoxic OR hypercapnic not specified |
| J96.01 | Acute respiratory failure, with hypoxia | PaO₂ <60 or SpO₂ <91% |
| J96.02 | Acute respiratory failure, with hypercapnia | PaCO₂ >45 mmHg |
| J96.10 | Chronic respiratory failure, unspecified | Long-standing CO₂ retention (COPD) |
| J96.20 | Acute and chronic respiratory failure | Acute-on-chronic |
| J80 | Acute respiratory distress syndrome (ARDS) | Bilateral infiltrates + PaO₂/FiO₂ <300 |
Sequencing rule: Acute respiratory failure CAN be the principal diagnosis when it is what chiefly drove the admission. It can also be a secondary diagnosis when it develops after admission. The choice affects DRG assignment and reimbursement significantly. - Health Information Associates, 2025
12-year-old admitted with moderate persistent asthma + acute hypoxemic respiratory failure (SpO₂ 82%)
- Principal Dx options: J45.41 (moderate persistent asthma, with acute exacerbation) OR J96.01 (acute hypoxemic respiratory failure)
- Coding tip: Using J96.01 as PDX → DRG 189 (higher resource intensity). Must be supported by documentation that respiratory failure drove the admission.
| ICD-10 Code | Description |
|---|---|
| J18.9 | Pneumonia, unspecified organism |
| J18.0 | Bronchopneumonia, unspecified |
| J15.211 | Pneumonia due to MRSA |
| J12.82 | Pneumonia due to coronavirus (non-COVID) |
| U07.1 | COVID-19 (always code first when confirmed) |
| J15.9 | Unspecified bacterial pneumonia |
Coding rule: For COVID-19 pneumonia → U07.1 first, then J12.89 (Other viral pneumonia). Never use J18.x for viral pneumonia.
| ICD-10 Code | Description |
|---|---|
| J84.10 | Pulmonary fibrosis, unspecified |
| J84.112 | Idiopathic pulmonary fibrosis (IPF) |
| J84.116 | Cryptogenic organizing pneumonia (COP) |
| J62.8 | Pneumoconiosis due to silica |
| J60 | Coalworkers' pneumoconiosis |
| ICD-10 Code | Description |
|---|---|
| J90 | Pleural effusion, not elsewhere classified |
| J93.11 | Primary spontaneous pneumothorax |
| J93.12 | Secondary spontaneous pneumothorax |
| J95.811 | Post-procedural pneumothorax |
| CPT Code | Procedure | What Triggers It |
|---|---|---|
| 94010 | Spirometry (FVC + FEV₁) | Asthma monitoring, COPD diagnosis |
| 94060 | Spirometry before AND after bronchodilator | Reversibility testing |
| 94150 | Vital capacity measurement | Restrictive lung disease workup |
| 94200 | Maximum breathing capacity (MVV) | Preoperative assessment |
| 94375 | Respiratory flow-volume loop | Upper airway obstruction workup |
| 94680 | O₂ uptake, expired gas analysis | Exercise testing, metabolic workup |
| 94760 | Non-invasive pulse oximetry (single) | Spot check SpO₂ |
| 94761 | Non-invasive pulse oximetry (multiple) | Monitoring over time |
| 94762 | Non-invasive pulse oximetry (nocturnal) | Sleep hypoxemia |
| 94002 | Mechanical ventilation initiation | ICU management |
| 94003 | Daily management of mechanical ventilation | Each subsequent day |
| 31500 | Emergency endotracheal intubation | Acute respiratory failure |
| 32551 | Chest tube insertion (tube thoracostomy) | Pneumothorax, empyema |
| 94640 | Non-invasive respiratory treatment (nebulizer) | Acute asthma/COPD exacerbation |
| 94644 | Continuous inhalation treatment (>1 hour) | Severe bronchospasm |
- Hypoxemia: Low O₂ in the blood (PaO₂ <75 mmHg or SpO₂ <91%)
- Hypoxia: Low O₂ delivery to the tissues
- You can have hypoxia without hypoxemia (e.g., severe anemia, CO poisoning - normal PaO₂ but hemoglobin cannot carry O₂)
- ICD-10: R09.02 (Hypoxemia), R09.01 (Asphyxia) - always require physician documentation
- J44.0 (COPD with acute lower respiratory infection) + organism code if specified
- Do NOT code J44.1 (COPD with acute exacerbation) and J44.0 together - they are mutually exclusive
- The pneumonia organism code goes second (e.g., J15.9 for bacterial)
- V/Q = Ventilation/Perfusion ratio. Normal = 0.8 (slightly more perfusion than ventilation)
- V/Q mismatch = the most common cause of hypoxemia
- Dead space (high V/Q): ventilated but not perfused → PE (I26.xx codes)
- Shunt (low V/Q): perfused but not ventilated → pneumonia, atelectasis, ARDS
- Coding: the underlying cause drives the code, not the V/Q mismatch itself
- Use J96.20 (Acute and chronic respiratory failure, unspecified) or J96.21 (with hypoxia) or J96.22 (with hypercapnia)
- Documentation must clearly say BOTH acute AND chronic components
- No absolute rule - it is a clinical diagnosis documented by the physician
- ABG supports it: PaO₂ <60 mmHg or PaCO₂ >50 mmHg generally
- SpO₂ <91% on room air with clinical distress qualifies even without ABG - HIA Coding, 2025
- Never assign J96.xx based on ABG values alone - the physician must document the diagnosis
- Asthma (J45.x): Reversible; classified by severity AND frequency (intermittent vs persistent) AND complication (uncomplicated, exacerbation, status asthmaticus)
- COPD (J44.x): Irreversible; classified by complication only (infection, exacerbation, unspecified)
- FEV₁/FVC <0.70 post-bronchodilator = COPD; documentation must support
- J44.9 + J45.40 = acceptable to code both when physician documents both diagnoses
- CPT 94002 = initiation of mechanical ventilation
- CPT 94003 = each subsequent day of management
- ICD-10: The underlying reason for ventilation is coded (e.g., J96.01, J80)
- Duration of mechanical ventilation affects MS-DRG: ≥96 hours triggers higher-paying DRG (DRG 003/004)
"Breathing is like a bellows pump controlled by the brain. The diaphragm drops, air rushes in. At the end of that journey - the alveolus - a paper-thin membrane lets oxygen diffuse into blood (driven by pressure difference from 100 to 40 mmHg) and lets CO₂ escape out. Hemoglobin in red cells carries 98.5% of that oxygen to every tissue. When this system fails, we see it on an ABG - pH drops, CO₂ rises, O₂ falls. As a coder, every failure point in this chain has a specific ICD-10 code: obstructed airway (J44, J45), damaged alveoli (J84, J80), flooded alveoli (J18), failed gas exchange (J96). Our job is to translate the physician's clinical story into the most precise, specific code supported by documentation."
breathing and exchange of gases in the respiratory system with Diagram
respiratory system anatomy airways alveoli gas exchange diagram

This medical illustration is a pathophysiology diagram depicting the human respiratory system and the deposition patterns of particulate matter (PM) based on size. The diagram utilizes a human silhouette to map the upper and lower respiratory tracts. Labeled anatomical regions include the nasal passages, pharynx, trachea, primary bronchi, bronchi branches, bronchioli, and alveoli. Each region is annotated with a specific PM size range (presumably in micrometers) that typically deposits there. The data shows a progressive decrease in particle size relative to the depth of penetration: the upper tract (nasal passages) captures larger particles (11–7 µm), the conductive airways (trachea and bronchi) capture mid-sized particles (4.7–1.1 µm), and the deepest acinar regions (bronchioli and alveoli) receive the smallest, ultrafine particles (1.1–0.43 µm). This visual serves as an educational tool for environmental health and pulmonology, illustrating how different particle diameters interact with respiratory anatomy to impact lung health.

This medical anatomical diagram illustrates the human respiratory system in a sagittal and coronal cross-section, specifically highlighting the deposition potential of particulate matter (PM) based on particle size (measured in micrometers) across various anatomical regions. The diagram maps specific PM ranges to key structures: the nasal passages (11-7 µm), pharynx (7-4.7 µm), trachea and primary bronchi (4.7-3.3 µm), bronchi branches (2.1-1.1 µm), bronchioli (1.1-0.65 µm), and the alveoli (0.65-0.43 µm). Visually, the image shows the transition from the upper respiratory tract to the lower deep lung structures, demonstrating a clear inverse relationship where larger particles are filtered in the upper airways and smaller, fine particles reach the terminal alveoli. This educational visual is relevant for environmental health, pulmonology, and pathophysiology, illustrating how inhaled pollutants distribute based on their aerodynamic diameter and the risk factors associated with deep pulmonary penetration of fine particulate matter.

This composite image illustrates the application of Virtual Reality (VR) in medical education and anatomical visualization. In the foreground, a user is depicted wearing a VR headset and holding handheld controllers, demonstrating an immersive interaction with a digital environment. The background features a detailed 3D anatomical rendering of the lower respiratory system, specifically focusing on the alveolar sacs. These structures are shown as clusters of spherical, textured modules in varying shades of brown and orange, simulating the microscopic anatomy of the lungs. Integrated into this visualization are thin, reddish tubular networks representing the pulmonary capillary system that surrounds the alveoli to facilitate gas exchange. A larger vessel with a blue lumen is also visible, likely representing a pulmonary artery branch. The image highlights the use of simulation technology to explore human physiology and pathophysiology, providing a tool for medical students and professionals to study organ systems in a highly interactive and spatially accurate manner.

This medical illustration is a stylized 3D anatomical diagram of the human respiratory system, focusing on the lungs and trachea. The central feature is a pair of symmetrically positioned lungs with a granulated, textured surface that evokes the presence of pulmonary parenchyma and alveoli. Connecting them at the superior midline is the trachea, depicted with visible horizontal ridges representing cartilaginous rings. The image utilizes a cool, high-contrast blue color palette with digital overlays—including binary code patterns and circular UI elements—to establish a clinical and technological aesthetic. This infographic-style visual represents the intersection of pulmonology and advanced diagnostic technology, specifically the application of deep learning algorithms and artificial intelligence in lung cancer imaging and nodule detection. The educational focus is on visualizing thoracic anatomy within the context of computer-aided diagnosis (CAD) and medical informatics.
breathing mechanics diaphragm lung inspiration expiration

This diagnostic imaging composite displays multi-planar CT reconstructions and 3D volume-rendered models of the human lungs to illustrate anatomical changes across breathing phases and body positions. The image is organized into four panels: axial (A), sagittal (B), coronal (C), and 3D volume rendering (D). Each panel compares 'Inspiration' and 'Expiration' phases across three postures: supine, standing, and sitting. The lung lobes are color-coded for identification: the right upper lobe (yellow), right middle lobe (blue), right lower lobe (green), left upper lobe (pink), and left lower lobe (purple). The visuals demonstrate significant vertical expansion and increased lung height during inspiration compared to expiration. In the upright positions (standing and sitting), the lungs show altered morphology compared to the supine position due to gravitational effects on the diaphragm and thoracic contents. The volume-rendered models in panel D highlight the relative volumetric changes of individual lobes, showing that the lower lobes exhibit the greatest expansion during inspiration. This educational material is designed to teach respiratory mechanics, gravitational physiology, and the clinical utility of upright CT imaging in pulmonary assessment.

This diagnostic imaging panel presents six sagittal views of the human thorax obtained using 3D ultrashort echo time (UTE) Magnetic Resonance Imaging (MRI). The images compare three respiratory patterns: normal breathing (left), thoracic breathing (middle), and diaphragmatic breathing (right), captured at two distinct phases: end-expiration (top row) and end-inspiration (bottom row). Red overlay curves on the inspiration images mark the lung boundaries from the corresponding expiratory state to highlight anatomical displacement. Red arrows indicate the primary direction of motion, emphasizing diaphragmatic descent and anterior-posterior chest wall expansion. The 'normal' column shows a combination of diaphragmatic and thoracic movement, while 'thoracic' breathing exhibits more pronounced anterior chest wall protrusion, and 'diaphragmatic' breathing shows maximal inferior displacement of the diaphragm. This visualization is part of a 3D MR Spirometry study used to analyze respiratory mechanics, pulmonary dynamics, and regional volume expansion, demonstrating how different breathing maneuvers affect lung parenchyma motion and thoracic cavity volume.

This diagnostic image provides a comparison of human respiratory dynamics using sagittal-view gated CT imaging across three breathing patterns: normal, thoracic, and diaphragmatic. The panel is organized into two rows representing physiological states: 'End of expiration' (top) and 'End of inspiration' (bottom). Each column highlights a specific respiratory technique. In the bottom row (inspiration), a red outline superimposes the lung border from the previous expiratory phase to visually demonstrate lung volume expansion. Red arrows indicate primary mechanical drivers for each pattern: the thoracic breathing column displays anterior movement of the chest wall, while the diaphragmatic breathing column emphasizes significant inferior displacement of the diaphragm and expansion of the lower thoracic cavity. This comparison illustrates the mechanical differences between costal and abdominal breathing, demonstrating how different muscle groups contribute to changes in pleural pressure and lung volume. The imagery serves as an educational tool for pulmonology and physiology, focusing on respiratory mechanics and accessory muscle recruitment.
oxygen carbon dioxide partial pressure gas exchange alveolar capillary blood

Educational diagnostic image demonstrating group statistical parametric maps (n=20) from an fMRI study. The figure illustrates the regional association between Blood Oxygen Level Dependent (BOLD) signal changes (ΔBOLD) and respiratory gas exchange (RGE) metrics: breath exchange ratio (bER), change in partial pressure of oxygen (ΔPO2), and change in partial pressure of carbon dioxide (ΔPCO2). Panel (A) displays group maps of regional ΔBOLD per unit change of these metrics (β values), showing widespread positive associations for bER and ΔPO2, while ΔPCO2 shows minimal significant association. Panel (B) presents the percentage of voxels with significant ΔBOLD associations, highlighting a higher density (over 50%) in gray matter regions for bER and ΔPO2 compared to white matter and compared to ΔPCO2. Panel (C) provides paired comparisons, specifically showing significant differences between bER and ΔPCO2 across subcortical regions and the brainstem. Color scales represent magnitude and percentage, with statistical significance corrected at pfdr < 0.05. The maps include axial, sagittal, and coronal anatomical views to demonstrate spatial distribution across the brain.

This diagnostic imaging figure presents a neuroimaging comparison using functional magnetic resonance imaging (fMRI) data from a group study (n=20). The image is divided into four rows of brain maps shown in axial, sagittal, and coronal planes. Row (A) displays group statistical parametric maps illustrating the association between Blood Oxygen Level-Dependent signal changes (ΔBOLD) and three respiratory gas exchange metrics: breath-by-breath Exchange Ratio (bER), partial pressure of oxygen (ΔPO2), and partial pressure of carbon dioxide (ΔPCO2). Heat maps (red-yellow indicating positive association) reveal significant coupling for bER and ΔPO2 across widespread cortical regions, particularly within the Default Mode Network (DMN), including the precuneus and posterior cingulate cortex. The association with ΔPCO2 is notably weaker and more localized. Row (B) shows a group functional connectivity map using a seed-based approach at the left precuneus. The spatial distribution of increased connectivity in the DMN highly correlates with the association patterns seen in the bER and ΔPO2 maps. Statistical significance is corrected at p_fdr < 0.05, demonstrating the relationship between systemic respiratory metrics and resting-state neural networks.

This physiological timecourse chart displays multi-modal data from a single human subject during a respiratory challenge and motor task. It is divided into three vertically aligned panels over a 900-second duration. Panel (a) shows the Blood Oxygen Level Dependent (BOLD) signal percentage change within a motor activation mask, exhibiting dynamic fluctuations and peak amplitudes reaching approximately 18% during periods of stimulation. Panel (b) illustrates end-tidal partial pressure of oxygen (PETO2) in mmHg, featuring two distinct step-wise increases to hyperoxic levels (~500 mmHg) between approximately 200–400 seconds and 550–700 seconds. Panel (c) tracks end-tidal partial pressure of carbon dioxide (PETCO2), which remains relatively stable around 44 mmHg with minor physiological oscillations. This data is used in calibrated BOLD fMRI studies to evaluate neurovascular coupling and oxygen extraction fraction (OEF) by correlating cerebral hemodynamic responses with controlled arterial gas changes.
Detailed medical educational diagram of breathing and gas exchange in the respiratory system. Show: 1) Full respiratory anatomy from nose/mouth down to alveoli with labels (nasal cavity, pharynx, larynx, trachea, bronchi, bronchioles, alveolar sacs). 2) Side-by-side comparison of INSPIRATION vs EXPIRATION showing diaphragm position (down during inspiration, up during expiration), rib cage expanding outward during inspiration, lungs inflating. 3) Close-up magnified view of a single alveolus surrounded by pulmonary capillary, showing O2 diffusing from alveolus into red blood cells (arrow labeled PO2 100→40 mmHg) and CO2 diffusing from blood into alveolus (arrow labeled PCO2 45→40 mmHg). 4) A pressure values table: Atmospheric air PO2=159mmHg, Alveolar PO2=100mmHg, Blood PO2=40mmHg arriving. 5) Color coding: blue for deoxygenated blood, red for oxygenated blood, light blue for air/airways. Clean white background, medical textbook style, fully labeled.


Key labels: (1) Transverse diameter increases; (2) Sagittal diameter increases; (3) Epigastric angle widens; (4) Diaphragm descends/flattens; (5) Vertical diameter increases - during INSPIRATION. All reverse during EXPIRATION. - Color Atlas of Human Anatomy Vol. 2
UPPER AIRWAY (Conducting Zone)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Nose / Mouth
↓ (filters, warms, humidifies air)
Nasal Cavity (turbinates, cilia, mucus)
↓
Pharynx (naso → oro → laryngopharynx)
↓
Larynx (epiglottis, vocal cords, cricoid cartilage)
↓
Trachea (18 cm long, C-shaped cartilage rings)
↓
Right & Left Primary Bronchi
↓
Secondary (Lobar) Bronchi → 3 right, 2 left
↓
Tertiary (Segmental) Bronchi
↓
Bronchioles (no cartilage, smooth muscle)
↓
Terminal Bronchioles ← LAST purely conducting zone
LOWER AIRWAY (Respiratory Zone)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Respiratory Bronchioles (first gas exchange begins)
↓
Alveolar Ducts
↓
Alveolar Sacs
↓
ALVEOLI ← Main site of gas exchange
(~300-500 million; total surface area ~70 m²)
| Cell Type | % of Surface | Function |
|---|---|---|
| Type I Pneumocytes | ~95% | Thin, flat - actual gas exchange surface |
| Type II Pneumocytes | ~5% | Produce surfactant (reduces surface tension, prevents collapse) |
| Alveolar Macrophages | - | Immune defense - "dust cells" |
The alveolar-capillary membrane is only 0.2-0.5 micrometers thick - thinner than a single red blood cell - maximizing diffusion efficiency.
Pressure × Volume = Constant When volume increases → pressure drops → air flows IN When volume decreases → pressure rises → air flows OUT
Brain (respiratory center) sends signal
↓
Diaphragm CONTRACTS → flattens/descends 1-3 cm
+ External intercostal muscles CONTRACT
+ (Deep breath): scalene & sternocleidomastoid assist
↓
Thoracic cavity EXPANDS in ALL dimensions:
• Vertical ↑ (diaphragm descends)
• Transverse ↑ (ribs swing up and out - "bucket handle")
• AP diameter ↑ (sternum moves forward - "pump handle")
↓
Intrapleural pressure drops: -5 → -8 cmH₂O
↓
Lung is pulled outward (adheres to thoracic wall)
↓
Alveolar pressure drops BELOW atmospheric:
760 mmHg (atm) → alveolar ~758 mmHg
↓
Air rushes IN (down the pressure gradient)
↓
Tidal Volume ~500 mL enters lungs
Respiratory muscles RELAX
↓
Elastic recoil of lung tissue and thoracic cage
↓
Thoracic volume DECREASES:
• Diaphragm domes move UPWARD
• Ribs return to resting position
↓
Intrapleural pressure returns: -8 → -5 cmH₂O
↓
Alveolar pressure RISES above atmospheric:
762 mmHg > 760 mmHg (atm)
↓
Air flows OUT
| Type | Mechanism | Who uses it |
|---|---|---|
| Thoracic breathing | Rib cage expansion via intercostal muscles | Adult females predominantly |
| Diaphragmatic (Abdominal) breathing | Diaphragm contraction pushes abdomen out | Adult males, infants, elderly |
Infants and older people rely chiefly on abdominal breathing - infants because of the horizontal position of ribs, the elderly because of diminished thoracic elasticity. - Color Atlas of Human Anatomy Vol. 2
An intact pleural cavity is necessary for normal breathing. If air enters from outside or inside the body, the negative pressure is lost and pneumothorax results. Without the capillary forces holding the lung against the chest wall, the elastic lung collapses to one-third of its original volume. - Color Atlas of Human Anatomy Vol. 2
┌──────────────────────────────────────┐
│ TOTAL LUNG CAPACITY ~6000 mL │
│ │
IRV 3100 mL ───────►│▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓│
│ Inspiratory Reserve Volume │
│───────────────────────────────────────│
TV 500 mL ────────►│░░░░░░░░░ Tidal Volume ░░░░░░░░░░│ ◄ Normal breath
│───────────────────────────────────────│
ERV 1200 mL ───────►│▒▒▒▒▒▒▒▒ Expiratory Reserve ▒▒▒▒│
│───────────────────────────────────────│
RV 1200 mL ───────►│████████ Residual Volume █████████│ ◄ Never exhaled
└──────────────────────────────────────┘
Key Derived Values:
• Vital Capacity (VC) = IRV + TV + ERV = ~4800 mL
• FEV₁/FVC > 0.70 = Normal
• FEV₁/FVC < 0.70 = OBSTRUCTIVE (COPD, Asthma)
• Reduced TLC = RESTRICTIVE (fibrosis, obesity)
| Location | PO₂ (O₂) | PCO₂ (CO₂) |
|---|---|---|
| Atmospheric air (dry) | 159 mmHg | 0.3 mmHg |
| Tracheal air (humidified) | 149 mmHg | 0.3 mmHg |
| Alveolar air | 100 mmHg | 40 mmHg |
| Deoxygenated blood arriving at alveolus | 40 mmHg | 45 mmHg |
| Oxygenated blood leaving alveolus | 95-100 mmHg | 40 mmHg |
| Tissue cells (metabolizing) | 20-40 mmHg | 46+ mmHg |
ALVEOLUS (air side)
┌─────────────────────────┐
│ PO₂ = 100 mmHg │
│ PCO₂ = 40 mmHg │
└────────┬────────────────┘
│ Alveolar-capillary membrane
│ (Type I pneumocyte + basement membrane
│ + capillary endothelium = 0.5 µm thick)
┌────────▼────────────────┐
│ PULMONARY CAPILLARY │
│ │
│ O₂ ENTERS: →→→→→→→ │ PO₂: 40 → 100 mmHg
│ (binds hemoglobin) │
│ │
│ CO₂ LEAVES: ←←←←←←← │ PCO₂: 45 → 40 mmHg
│ (expelled in expiration)│
└─────────────────────────┘
O₂ in blood (100 mL):
┌─────────────────────────────────────┐
│ Bound to HEMOGLOBIN → 98.5% │ (forms oxyhemoglobin, HbO₂)
│ Dissolved in plasma → 1.5% │ (measured as PaO₂)
└─────────────────────────────────────┘
Each hemoglobin molecule:
• 1 Hb = 4 heme groups = 4 O₂ molecules carried
• Fully saturated = 20 mL O₂ per 100 mL blood
• Normal SaO₂ = 95-100%
SaO₂ (%)
100% ─────────────────────╮
│ FLAT PART (lungs):
90% ──────────────────╮ │ Small PO₂ changes = minimal
│ │ saturation change (protective)
75% ─────────────╮ │ │
│ │ STEEP PART (tissues):
50% ─────────╮ │ │ │ Small PO₂ drop = large O₂
│ │ │ │ release (efficient delivery)
25% ──────╮ │ │ │
│ │ │ │
0% ──────┴──┴───┴────┴────────►
20 40 60 80 100 PO₂ (mmHg)
SYSTEMIC CAPILLARY (tissue level)
Oxygenated blood arriving:
PO₂ = 95 mmHg → Tissue PO₂ = 20-40 mmHg
↓
O₂ UNLOADS from HbO₂ → diffuses INTO cells
Cells use O₂ in mitochondria for ATP production
CO₂ produced by cells:
PCO₂ tissue = 46+ mmHg → blood PCO₂ = 40 mmHg
↓
CO₂ diffuses OUT of cells INTO blood
CO₂ Transport back to lungs:
┌──────────────────────────────────────┐
│ As Bicarbonate (HCO₃⁻) → 70% │ ← CO₂ + H₂O ⇌ H₂CO₃ ⇌ H⁺ + HCO₃⁻
│ Bound to Hemoglobin → 23% │ ← Carbaminohemoglobin
│ Dissolved in plasma → 7% │ ← PCO₂
└──────────────────────────────────────┘
BRAINSTEM RESPIRATORY CENTER
┌─────────────────────────────┐
│ Pre-Bötzinger Complex │ ← Sets basic rhythm
│ Dorsal Resp Group (DRG) │ ← Inspiration
│ Ventral Resp Group (VRG) │ ← Forced expiration
└──────────┬──────────────────┘
│
┌─────────▼──────────┐
│ Chemoreceptors │
│ │
│ Central (Medulla) │ ← Most sensitive to CO₂/pH
│ ↑ PCO₂ → ↑RR │ (responds via CSF H⁺)
│ │
│ Peripheral │ ← Carotid & aortic bodies
│ (Carotid/Aortic) │ Respond to ↓O₂, ↑CO₂, ↓pH
└────────────────────┘
Clinical note (COPD): Patients with chronic CO₂ retention lose sensitivity to CO₂ and depend on "hypoxic drive" (low O₂). Giving high-flow O₂ to a COPD patient can remove this drive and cause respiratory depression - always use controlled O₂ delivery.
1. INHALE
Air (PO₂=159) → warmed, humidified → Alveolar air (PO₂=100)
2. ALVEOLAR EXCHANGE
O₂ diffuses: alveolus (PO₂=100) → blood (PO₂=40)
CO₂ diffuses: blood (PCO₂=45) → alveolus (PCO₂=40)
3. OXYGENATED BLOOD LEAVES LUNGS
Via pulmonary veins → Left heart → AORTA
Blood: PO₂=95, SaO₂=98%, deep red
4. SYSTEMIC DELIVERY
Aorta → arteries → arterioles → tissue capillaries
O₂ unloads (Bohr effect at working tissues)
CO₂ loads
5. DEOXYGENATED BLOOD RETURNS
Via venules → veins → vena cava → Right heart
Blood: PO₂=40, SaO₂=75%, dark purple-red
6. PULMONARY CIRCULATION
Right ventricle → Pulmonary artery → Lung capillaries
Cycle RESTARTS
Normal rate: 12-20 breaths/minute
Each cycle: ~4 seconds
Total O₂ consumed at rest: ~250 mL/min
Total CO₂ produced at rest: ~200 mL/min
| Parameter | Normal Value | Clinical Significance |
|---|---|---|
| Respiratory rate | 12-20/min | <12 = hypoventilation; >20 = tachypnea |
| Tidal volume | 500 mL | Reduced in restrictive disease |
| FEV₁/FVC | >0.70 | <0.70 = obstructive disease |
| PaO₂ | 75-100 mmHg | <60 = significant hypoxemia |
| PaCO₂ | 35-45 mmHg | >45 = hypoventilation; <35 = hyperventilation |
| SaO₂ | 95-100% | <91% = hypoxemia requiring O₂ |
| pH | 7.35-7.45 | <7.35 = acidemia; >7.45 = alkalemia |
| Alveolar-arterial O₂ gradient | <15 mmHg | >15 = V/Q mismatch, diffusion problem, shunt |
| DLCO | >75% predicted | Reduced in emphysema, fibrosis, anemia |